RT Journal Article
T1 Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: A Cohort Study.
A1 Ribó-Coll, Margarita
A1 Castro-Barquero, Sara
A1 Lassale, Camille
A1 Sacanella, Emilio
A1 Ros, Emilio
A1 Toledo, Estefanía
A1 Sorlí, José V
A1 Díaz-López, Andrés
A1 Lapetra, José
A1 Muñoz-Bravo, Carlos
A1 Arós, Fernando
A1 Fiol, Miquel
A1 Serra-Majem, Lluis
A1 Pinto, Xavier
A1 Castañer, Olga
A1 Fernández-Lázaro, César I
A1 Portolés, Olga
A1 Babio, Nancy
A1 Estruch, Ramón
A1 Hernáez, Álvaro
K1 antianginal drugs
K1 antihypertensive drugs
K1 antiplatelet drugs
K1 cardiac glycosides
K1 fibrates
K1 glucose-lowering drugs
K1 mediterranean diet
K1 physical activity
K1 statins
K1 vitamin K epoxide reductase inhibitors
AB Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71-0.80]), antihypertensive (HR: 0.79 [0.75-0.82]), statin (HR: 0.82 [0.78-0.85]), fibrate (HR: 0.78 [0.68-0.89]), antiplatelet (HR: 0.79 [0.75-0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74-0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56-0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180-360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction
SN 2076-3921
YR 2021
FD 2021-03-05
LK https://hdl.handle.net/10668/24807
UL https://hdl.handle.net/10668/24807
LA en
DS RISalud
RD Apr 8, 2025